A Vancouver-based research team led by Canada’s most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enough, a daily regimen of the non-prescription NSAID (nonsteroidal anti-inflammatory drug) ibuprofen can prevent the onset of Alzheimer’s disease.
This means that by taking an over-the-counter medication, people can ward off a disease that, according to Alzheimer’s Disease International’s World Alzheimer Report 2016, affects an estimated 47 million people worldwide, costs health care systems worldwide more than US$818 billion  per year and is the fifth leading cause of death in those aged 65 or older.
The Alzheimer’s Association estimates that there are more than 5 million cases in the United States alone, with a new case being identified every 66 seconds. The annual cost to the country in 2017 is estimated have been US$259 billion, with that figure predicted to potentially rise to US$1.1 trillion  by 2050.
Dr. McGeer, who is President and CEO of Vancouver-based Aurin Biotech, and his wife, Dr. Edith McGeer, are among the most cited neuroscientists in the world. Their laboratory is world-renowned for their 30 years of work in neuroinflammation and neurodegenerative diseases, particularly Alzheimer’s disease. A paper detailing Dr. McGeer’s most recent discoveries has been published in the prestigious Journal of Alzheimer’s Disease.
In 2016, Dr. McGeer and his team announced that they had developed a simple saliva test that can diagnose Alzheimer’s disease, as well as predict its future onset. The test is based on measuring the concentration of the peptide amyloid-beta protein 42 (Abeta 42) secreted in saliva. In most individuals, the rate of Abeta 42 production is almost exactly the same regardless of sex or age. However, if that rate of production is two to three times higher, those individuals are destined to develop Alzheimer’s disease. That is because Abeta 42 is a relatively insoluble material, and although it is made everywhere in the body, deposits of it occur only in the brain, causing neuroinflammation, which destroys neurons in the brains of people with Alzheimer’s disease.
Contrary to the widely held belief that Abeta 42 is made only in the brain, Dr. McGeer’s team demonstrated that the peptide is made in all organs of the body and is secreted in saliva from the submandibular gland. As a result, with as little as one teaspoon of saliva, it is possible to predict whether an individual is destined to develop Alzheimer’s disease. This gives them an opportunity to begin taking early preventive measures such as consuming non-prescription non-steroidal drugs (NSAIDs) such as ibuprofen.
“What we’ve learned through our research is that people who are at risk of developing Alzheimer’s exhibit the same elevated Abeta 42 levels as people who already have it; moreover, they exhibit those elevated levels throughout their lifetime so, theoretically, they could get tested anytime,” says Dr. McGeer. “Knowing that the prevalence of clinical Alzheimer’s Disease commences at age 65, we recommend that people get tested ten years before, at age 55, when the onset of Alzheimer’s would typically begin. If they exhibit elevated Abeta 42 levels then, that is the time to begin taking daily ibuprofen to ward off the disease.
“Unfortunately, most clinical trials to date have focused on patients whose cognitive deficits are already mild to severe, and when the therapeutic opportunities in this late stage of the disease are minimal. Consequently, every therapeutic trial has failed to arrest the disease’s progression. Our discovery is a game changer. We now have a simple test that can indicate if a person is fated to develop Alzheimer’s disease long before it begins to develop. Individuals can prevent that from happening through a simple solution that requires no prescription or visit to a doctor. This is a true breakthrough since it points in a direction where AD can eventually be eliminated.”
The Latest on: Alzheimer’s disease
via Google News
The Latest on: Alzheimer’s disease
- Research finds ethnoracial differences in Alzheimer's disease on February 22, 2019 at 2:30 am
JACKSONVILLE, Fla. - A team of Mayo Clinic researchers found Hispanic-American patients with Alzheimer's tend to survive significantly longer with the disease than other ethnoracial groups, according ... […]
- A joyful existence with Alzheimer's? More people are trying this different approach. on February 22, 2019 at 1:45 am
He grinned wryly at his wife. "That's Ollie talking." Ollie is their nickname for Alzheimer's, the disease Tom was diagnosed with seven years ago. For the Misciagnas, Ollie is a third presence in the ... […]
- Alzheimer's Disease Current Treatments and Potential New Agents on February 21, 2019 at 9:24 pm
Alzheimer's disease (AD) is becoming more prevalent worldwide. Four medications (donepezil, rivastigmine, galantamine, and memantine) are approved to treat AD symptoms. Despite extensive research over ... […]
- Tyler recognized as Dementia Friendly Community; efforts to increase awareness of the disease underway on February 21, 2019 at 4:35 pm
An uncontrollable outburst or failure to remember familiar names or faces can cause those living with dementia to needlessly withdraw from public life. Alzheimer’s Alliance of Smith County ... […]
- Classifying Alzheimer's may help in detecting and treating the disease on February 21, 2019 at 8:29 am
ORLANDO -- (02/21/2019) -- Right now, 5.7 million Americans are living with Alzheimer’s disease. That number is expected to exceed 14 million by 2050. While there’s no cure for this common brain disea... […]
- Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity on February 21, 2019 at 2:24 am
Alzheimer’s Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. A growing body of evidence indicates that cognitive, behavioral, sensory, and motor changes may prec... […]
- Possible pathway to new therapy for Alzheimer's disease on February 19, 2019 at 1:30 pm
Researchers have uncovered an enzyme and a biochemical pathway they believe may lead to the identification of drugs that could inhibit the production of beta-amyloid protein, the toxic initiator ... […]
- Alzheimer’s Disease and Exercise on February 19, 2019 at 6:05 am
sLeptin is back at it again! Since our group presented this week about the role of myokines in exercise, we thought it would only be appropriate to revisit the topic of exercise and further ... […]
- Could a blood test predict Alzheimer's disease 16 years before symptoms? on February 19, 2019 at 3:04 am
Could a blood test diagnose Alzheimer's disease up to 16 years before a person begins showing symptoms? The chief executive at Lexington-based Quanterix Corp. believes so. Clinical trial data publishe... […]
via Bing News